[24] 吴委。万古霉素群体药动学及个体化给药研究[D]. 福建医科大学， 20xx.

　　[25] Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summaryof consensus recommendations from the infectious diseases Society of America, the American Societyof Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists[J]. Clinicalinfectious diseases : an official publication of the Infectious Diseases Society of America, 20xx,49(3)：325-327.

　　[26] Farber BF, Moellering RC, Jr. Retrospective study of the toxicity of preparations of vancomycinfrom 1974 to 1981[J]. Antimicrobial agents and chemotherapy, 1983,23(1)： 138-141.

　　[27] Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era ofincreasing doses[J]. Antimicrobial agents and chemotherapy, 20xx,53(2)： 483-486.

　　[28] Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations andnephrotoxicity: a prospective multicenter trial[J]. Antimicrobial agents and chemotherapy, 20xx,55(12)：5475-5479.

　　[29] Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics ofpharmacokinetic parameters from routine clinical data[J]. Journal of pharmacokinetics andbiopharmaceutics, 1977,5(5)： 445-479.

　　[30] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine[J]. Nephron,1976,16(1)： 31- 41.

　　[31] Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokineticmodeling[J]. Journal of clinical pharmacology, 20xx,43(6)： 610-623.

　　[32] 叶红波。 NONMEM 法群体药代动力学研究的自举法验证及其应用[J]. 医学研究生学报，20xx,23(12)。

　　[33] Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an applicationto the population pharmacokinetics of gliclazide[J]. Pharmaceutical research, 20xx,23(9)： 20xx-2049.

　　[34] Ren YP, Deng CH, Wang XP, et al. Comparison study of model evaluation methods: normalizedprediction distribution errors vs. visual predictive check[J]. Yao Xue Xue Bao, 20xx,46(9)： 1123-1131.

　　[35] Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtrationrate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group[J]. Ann Intern Med, 1999,130(6) : 461-470.

　　[36] Levey A, Greene T, Kusek J, et al. A simplified equation to predict glomerular filtration rate fromserum creatinine[J]. J Am Soc Nephrol, 20xx,11(Suppl 2)： 155.

　　[37] Toto RD, Kirk KA, Coresh J, et al. Evaluation of serum creatinine for estimating glomerularfiltration rate in African Americans with hypertensive nephrosclerosis: results from theAfrican-American Study of Kidney Disease and Hypertension ( AASK) Pilot Study[J]. J Am SocNephrol, 1997,8(2)： 279-287.

　　[38] Nankivell BJ, Gruenewald SM, Allen RD, et al. Predicting glomerular filtration rate after kidneytransplantation[J]. Transplantation, 1995,59(12)： 1683-1689.

　　[39] 毕增祺， 徐红， 主理群。 对几种测定老年人肾小球滤过率方法的评估[J]. 中华老年医学杂志，20xx,25(1) : 25-28.

　　[40] Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin usingserum cystatin C as a marker of renal function[J]. Antimicrobial agents and chemotherapy, 20xx,54(2)：778-782.

　　[41] Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of populationpharmacokinetic analyses[J]. Clin Pharmacokinet, 20xx,51(1)： 1-13.

　　[42] 唐勤， 葛卫红， 丁义涛。 万古霉素对肝移植并发腹腔感染的治疗监测及药动学研究[J]. 江苏药学与临床研 究， 20xx,10(02)： 4-6.

　　[43] Revilla N, Martín‐Suárez A, Pérez MP, et al. Vancomycin dosing assessment in intensive care unitpatients based on a population pharmacokinetic/pharmacodynamic simulation[J]. British journal ofclinical pharmacology, 20xx,70(2)： 201- 212.

　　[44] Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin andvancomycin in patients with unstable renal function following cardiothoracic surgery[J]. British journalof clinical pharmacology, 20xx,61(2)： 164- 176.

　　[45] 胡瑾瑜， 施耀国， 张菁，等。 万古霉素在健康老年人和年轻人的药代动力学[J]. 中国抗感染化疗杂志， 20xx,3(3)： 138-142.

　　[46] 毕明慧。 老年重症感染患者使用万古霉素的'疗效及安全性分析[J]. 北京医学， 20xx,33(06)：491-493.

　　[47] Mizokami F, Shibasaki M, Yoshizue Y, et al. Pharmacodynamics of vancomycin in elderlypatients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquiredpneumonia[J]. Clinical interventions in aging, 20xx,8: 1015- 1021.